



कर्मचारी राज्य बीमा निगम
(श्रम एवं रोजगार मंत्रालय, भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)



मुख्यालय/HEADQUARTERS
पंचदीप भवन, सी.आई.जी. मार्ग, नई दिल्ली -110 002
Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002
www.esic.gov.in, ☎011-23604773, ✉dmc-rc@esic.nic.in

U-25/12/Misc/2021-MedVP-I

233

Dated: 07-07-2026

To,

Director (Medical) Delhi / Director (Medical) Noida,
Dean, All ESIC PGIMSR's, Medical & Dental Colleges
Medical Superintendents - All ESIC Hospitals,
Directors, ESI Scheme, All States

Sub: Precautionary Suspension of the Use of Bupivacaine Injections Manufactured by M/s Themis Medicare Ltd. - reg.

It is informed that the Employees' State Insurance Corporation (ESIC) Headquarters has taken cognizance of an Urgent Advisory dated 29.06.2026 issued by the Indian Society of Anaesthesiologists (ISA) advising discontinuation of the use of Bupivacaine manufactured by M/s Themis Medicare Ltd. pending completion of the ongoing investigation into reported serious adverse events.

Accordingly, as a precautionary measure and in the interest of patient safety, all ESIC Medical Colleges, Hospitals, Model Hospitals, Dispensaries and other Medical Institutions are hereby advised to immediately suspend the use of the following products manufactured by M/s Themis Medicare Ltd. until further orders from ESIC Headquarters:

1. **Bupivacaine Heavy Injection 0.5% - 4 ml**
2. **Bupivacaine Hydrochloride Injection 0.25% - 20 ml**

All concerned institutions shall:

- Immediately stop issuing and using the above-mentioned products.
- Segregate and quarantine the available stock to prevent inadvertent use.
- Maintain batch-wise inventory of the quarantined stock.
- Report immediately to ESIC Headquarters if any adverse event or suspected quality issue related to the above products has been observed.

This advisory is purely precautionary and is being issued without prejudice to the outcome of the ongoing investigation by the competent authorities and the clarification sought from the manufacturer. Further instructions shall be issued separately based on the outcome of the investigation.

This may be treated as MOST URGENT.

This issues with the approval of the competent authority.

Encl.: As above.

Yours Sincerely,

Digitally signed by
Sanjiv Kochhar
Date: 08-07-2026
11:11:29

Deputy Medical Commissioner

(RC/PC)

**ISA****Indian Society of
Anaesthesiologists**

INDIAN SOCIETY OF ANAESTHESIOLOGISTS

(Founder Member of the World Federation of Societies of Anaesthesiologists)

Regd No.8/1999 CHENNAI, PAN AAAT13385A, 80G DIT(E)NO2(372)/98-99 DATED:05.06.2000

President**Dr Naveen Malhotra****Mob.:9812091051****drnaveenmalhotra@yahoo.co.in****Vice-President****Dr C Rradha Kishen Rao****Mob.:9246119501****dr_crk Rao@rediffmail.com****Honorary Secretary****Dr Rajiv Gupta****Mob.:9811084288****rajiv_rita@yahoo.com****Treasurer****Dr Sunil Sethi****Mob.:9812091051****drsunilsethi@yahoo.co.in**

29-06-2026

URGENT IMPORTANT ADVISORY FROM ISA NATIONAL

All anaesthesiologists across the country are hereby strongly advised **to immediately stop using the bupivacaine manufactured by Themis for spinal anaesthesia and other purposes.** This advisory is being issued based on serious adverse events reported by the use of above drug for Spinal Anaesthesia. The investigations are going on, so you are advised not to use Bupivacaine manufactured by Themis until further notice.

This advisory is issued in the interest of patient safety and welfare.

Thank you.

Dr. Naveen Malhotra**President****Indian Society of Anaesthesiologists****Dr. Rajiv Gupta****Hon. Secretary****Indian Society of Anaesthesiologists**ISA Registered Office

ISA Balakrishnan House, No. 1203, Casagrand Monte Carlo, Anna Salai, NGR Colony, Saidapet, Chennai, Tamil Nadu-600015

ISA National President Office

Naveen Niketan, 128/19, Doctors Lane, Civil Hospital Road, Rohtak-124001, Haryana, India

E-mail: presidentisanhq@gmail.com, M: 9091515151

ISA National Head Quarters

B-231, Ashok Vihar, Phase-1, Delhi-110052, India

E-mail: secretaryisanhq@gmail.com, isanhq@gmail.com, M:9821088200 www.isaweb.in